$OXIS Analyst Coverage

OXIS International, Inc. (OXIS) is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a broad range of disease areas. Currently, it develops innovative drugs focused on the treatment of cancer and other unmet medical needs. The company positioned itself at the focal point of one of the highest-growth potential markets, immunotherapy market. Moreover OXIS can benefit from tremendous market opportunity in cannabinoid immunotherapy.

An analyst report on OXIS that includes a company overview, market and competition breakdown, recent events, outlook, valuation, analyst summary and recommendation can be viewed by using the following link:

https://bit.ly/OXIS_Analyst_Report

About Midam IR

Midam IR Inc. is the next generation of financial communication. We offer a full suite of services including IR, media marketing, content creation, advertising, and direct relationships with PR contacts that have afforded our clients the ability to have their corporate message reach beyond traditional channels. Midam is focused on helping publicly traded companies get their story & product out to the targeted masses, aiding in the acquisition of new shareholders, both on a retail & institutional level as well as the increase in revenue from corporate product sales.

Midam utilizes public relations, traditional & digital investor relations and brand / product marketing. Our talented and tested team delivers results driven strategies, unbeatable execution and an ever-expanding body of digital and traditional marketing expertise that delivers. Midam’s management team has a wealth of experience working with NASDAQ, NYSE and AMEX companies, which has given them ability to build the most comprehensive & affective platform available today for public companies.

With offices in Miami, & New Jersey, Midam has an expansive reach within the financial world along with a robust platform of services and products.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the company website.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at info@midamir.com. For any urgent concerns or inquiries please contact us at info@midamir.com.

Contact:

info@midamir.com

SOURCE: Midam IR